Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) CEO David James Lennon sold 9,689 shares of the stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $1.94, for a total value of $18,796.66. Following the transaction, the chief executive officer now directly owns 22,869 shares of the company’s stock, valued at $44,365.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Aadi Bioscience Price Performance
NASDAQ AADI traded down $0.04 on Thursday, hitting $1.92. 90,385 shares of the company were exchanged, compared to its average volume of 291,698. The company’s 50 day moving average price is $1.68 and its 200-day moving average price is $1.77. Aadi Bioscience, Inc. has a twelve month low of $1.21 and a twelve month high of $5.70. The firm has a market capitalization of $47.14 million, a P/E ratio of -0.77 and a beta of 0.69.
Aadi Bioscience (NASDAQ:AADI – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.17. Aadi Bioscience had a negative net margin of 274.77% and a negative return on equity of 66.67%. The business had revenue of $6.18 million for the quarter, compared to analyst estimates of $6.33 million. During the same period in the previous year, the business earned ($0.67) EPS. As a group, equities analysts expect that Aadi Bioscience, Inc. will post -2.02 EPS for the current year.
Institutional Investors Weigh In On Aadi Bioscience
Analyst Ratings Changes
Several brokerages recently issued reports on AADI. Piper Sandler Companies lowered Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 target price on the stock. in a research report on Tuesday, August 27th. Jefferies Financial Group cut Aadi Bioscience from a “buy” rating to a “hold” rating and decreased their price objective for the company from $11.00 to $1.50 in a report on Wednesday, August 21st. TD Cowen lowered shares of Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Piper Sandler cut Aadi Bioscience from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $5.00 to $1.75 in a research report on Tuesday, August 27th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Aadi Bioscience in a research report on Wednesday, August 21st. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.25.
Read Our Latest Report on Aadi Bioscience
About Aadi Bioscience
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
Featured Articles
- Five stocks we like better than Aadi Bioscience
- 3 Warren Buffett Stocks to Buy Now
- When Is the Best Time to Invest in Mutual Funds?
- Buy P&G Now, Before It Sets A New All-Time High
- Is NVIDIA Stock in a Correction or Consolidation?
- What is a Stock Market Index and How Do You Use Them?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.